FAP promotes metastasis and chemoresistance via regulating YAP1 and macrophages in mucinous colorectal adenocarcinoma

Mucinous colorectal adenocarcinoma (MC) is less likely to respond to chemo-therapy and is associated with poorer prognosis compared with non-MC (NMC). Fibroblast activation protein (FAP) was found and validated to be upregu-lated in MC patients and was negatively correlated with prognosis and therapeu-tic outcomes in colorectal cancer (CRC) patients who were treated with adjuvant chemotherapy. Overexpression of FAP promoted CRC cell growth, invasion and metastasis, and enhanced chemoresistance. Myosin phosphatase Rho-interacting protein (MPRIP) was identified as a direct interacting protein of FAP. FAP may in-fluence the efficiency of chemotherapy and prognosis by promoting the crucial functions of CRC and inducing tumor-associated macrophages (TAMs) recruit-ment and M2 polarization through regulating theRas Homolog Family Member/ Hippo/Yes-associated protein (Rho/Hippo/YAP) signaling pathway. Knockdown of FAP could reverse tumorigenicity and chemoresistance in CRC cells. Thus, FAP may serve as a marker for prognosis and therapeutic outcome, as well as a potential therapeutic target to overcome chemoresistance in MC patients.

Automated summary

Mucinous colorectal adenocarcinoma (MC) has poor response to chemotherapy and prognosis compared to non-MC (NMC). Fibroblast activation protein (FAP) is upregulated in MC patients and negatively correlated with prognosis and therapeutic outcomes in CRC patients. FAP promotes CRC cell growth, invasion, metastasis, and chemoresistance. Myosin phosphatase Rho-interacting protein (MPRIP) is a direct interacting protein of FAP. FAP influences chemotherapy efficiency and prognosis by promoting crucial CRC functions and inducing recruitment of tumor-associated macrophages (TAMs) and M2 polarization through the Rho/Hippo/YAP signaling pathway. Knockdown of FAP reverses tumorigenicity and chemoresistance in CRC cells. FAP may serve as a marker for prognosis and therapeutic target to overcome chemoresistance in MC patients.